Navigation Links
RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Date:12/4/2013

n the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contacts

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Products Company, Inc. has announced the addition of Florida ... Systems. Florida Metrology, based in Jupiter, ... Systems is a line of highly accurate portable metrology ... across the United States. Tim Row of Florida Metrology ...
... FOUNTAIN HILLS, Ariz., Dec. 8, 2010 Sunridge International ... that Ameco Medical is preparing to start the short ... Ameco Medical Equipment L.L.C., Sunridge,s exclusive distributor for ... Bores, Sunridge,s medical consultant, to attend the start of ...
Cached Medicine Technology:Florida Metrology To Distribute OASIS Inspection Systems 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... INDIANAPOLIS An orphan drug originally used for HIV treatment ... additional sensitivity and pain from opioid use. The study by ... in the March 25, 2011 issue of Brain, Behavior ... in animal models may ultimately make morphine a safer and ...
... , THURSDAY, March 24 (HealthDay News) -- Children ... control more quickly and accurately than those without the ... characterized by repeated involuntary sounds and physical movements called ... or -- in rare adult cases -- blurting out ...
... is available in French and Spanish . ... of Granada , belonging to the Laboratorio de Ciencias de la ... night vision, and the tool required to implement it, which has ... Software Halo v1.0, and a computer where the mouse is used ...
... Nick Harvey of the MRC Lifecourse Epidemiology Unit, Southampton, ... of Lige, Lige, Belgium were presented with the ESCEO ... at a ceremony held during the European Congress on ... Spain. The Awards, valued at 2,500, recognize young ...
... China, investigated eye movements in Chinese and British people to ... how they compare between different human populations. They found ... British people, is much more common in Chinese people, suggesting ... different populations. Tests of eye movements can ...
... Even mild stress can cause long-term disability that prevents people ... been known that mental disorders can be a cause of ... forms of stress should be taken more seriously, according to ... Kingdom, and colleagues. The study included over 17,000 employed ...
Cached Medicine News:Health News:A safer, more effective morphine may be possible with Indiana University discovery 2Health News:Children With Tourette Syndrome Have Better Motor Control, Study Finds 2Health News:Researchers develop a halometer that tests alterations in night vision 2Health News:Researchers develop a halometer that tests alterations in night vision 3Health News:Eye movement differs in British and Chinese populations 2Health News:Even Mild Stress Can Lead to Disability, Study Says 2
... offers accuracy, speed, ease of use, ... is an Auto Refractor/Keratometer with both ... elevation, automatic alignment, focusing, printing, high-speed ... other features that have made the ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
Neomycin and Polymyxin B sulfates and Dexamethasone ophthalmic ointment is a multiple dose anti-infective steroid combination in sterile ointment form for topical applications....
Medicine Products: